Analytical Data
-
Gene name
APOA1BP
- Application
-
Alternative Names
Apo-A1BP; AIBP; YJEFN1; NAD(P)H-hydrate epimerase; NAD(P)HX epimerase; YjeF N-terminal domain-containing protein 1
-
Species
Pig
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q0PIT9
-
Expression Region
Leu60~Gln288
-
Molecular Weight
55kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
APOA1BP (Apolipoprotein A1 Binding Protein) is a key protein implicated in lipid metabolism and cardiovascular health. Research into APOA1BP has gained momentum due to its potential role in modulating high-density lipoprotein (HDL) levels, which are crucial for preventing atherosclerosis and cardiovascular diseases. The protein interacts with apolipoprotein A1 (ApoA1), the primary protein component of HDL, influencing its stability and functionality. Disruptions in this interaction may contribute to lipid disorders and metabolic syndromes. Furthermore, studies suggest that APOA1BP may have a role in cellular cholesterol transport and regulation, highlighting its importance in maintaining cellular homeostasis. Given the increasing prevalence of cardiovascular diseases worldwide, understanding the molecular mechanisms governing lipid metabolism through proteins like APOA1BP has become critical. Researchers are focused on characterizing the structure and function of recombinant APOA1BP to explore its potential as a therapeutic target. Insights into the protein's role in HDL biogenesis and metabolism could pave the way for novel strategies in managing dyslipidemia and associated cardiovascular risks. Efforts to develop recombinant forms of APOA1BP aim to facilitate functional assays and therapeutic applications, emphasizing the need for continued investigation in this area to unravel the complexities of lipid-associated health conditions.
